Cerulean Pharma Appoints Business Development Manger

Cerulean Pharma Appoints Business Development Manger

Andres Tellez to help lead business development and partnering activities


CAMBRIDGE, Mass. – September 27, 2012 – Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Andres Tellez as Senior Manager of Business Development.

Dr. Tellez most recently served as Senior Manager of Business Development at Biocodex USA, a niche pharmaceutical company specializing in Gastroenterology, Oncology Supportive Care and Pediatric Neurology. During his time with Biocodex, he focused on transactions in Oncology Supportive Care. Dr. Tellez was previously a consultant with C1 Consulting, a strategy and market research consulting firm, where he performed forecasting and market research engagements for targeted therapies in solid tumor oncology.

Dr. Tellez earned a B.S. and a Masters of Engineering and Computer Science from MIT.  He earned a Ph.D. in Biomedical Informatics from Stanford University, where he also completed his Post-Doc.

"We are pleased to have Andres join Cerulean at this very exciting time in our corporate evolution," said Chris Guiffre, Senior Vice President and Chief Business Officer of Cerulean. "Andres brings a wealth of knowledge and experience to this key position, and he will contribute greatly to the various BD initiatives that will be key to our continued success."

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.


 

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.